Get the Stockscreener App
5.10
4.51%
0.22
After Hours:
5.15
0.05
+0.98%
Mannkind Corp stock is traded at $5.10, with a volume of 4.52M.
It is up +4.51% in the last 24 hours and down -8.44% over the past month.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
See More
Previous Close:
$4.88
Open:
$4.92
24h Volume:
4.52M
Relative Volume:
1.06
Market Cap:
$1.56B
Revenue:
$248.37M
Net Income/Loss:
$11.74M
P/E Ratio:
102.00
EPS:
0.05
Net Cash Flow:
$18.24M
1W Performance:
-9.89%
1M Performance:
-8.44%
6M Performance:
+9.44%
1Y Performance:
-21.30%
1-Day Range:
$4.895
$5.15
1-Week Range:
$4.79
$5.75
52-Week Range:
$3.3812
$7.63
Mannkind Corp Stock (MNKD) Company Profile
Name
Mannkind Corp
Sector
Industry
Phone
818-661-5000
Address
1 CASPER STREET, DANBURY, CA
Compare MNKD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
5.10 | 1.50B | 248.37M | 11.74M | 18.24M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | Leerink Partners | Outperform |
| Jul-16-25 | Resumed | H.C. Wainwright | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-10-25 | Initiated | Wedbush | Outperform |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-10-23 | Initiated | Wedbush | Outperform |
| May-14-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-24-19 | Initiated | Oppenheimer | Outperform |
| Oct-25-19 | Initiated | Cantor Fitzgerald | Overweight |
| May-14-19 | Initiated | BTIG Research | Buy |
| Mar-04-19 | Initiated | SVB Leerink | Outperform |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Feb-28-18 | Downgrade | Maxim Group | Hold → Sell |
| Nov-01-17 | Downgrade | Maxim Group | Buy → Hold |
| Oct-10-17 | Initiated | H.C. Wainwright | Buy |
| Oct-06-17 | Reiterated | Maxim Group | Buy |
| Aug-11-17 | Initiated | Maxim Group | Buy |
| May-10-16 | Reiterated | Piper Jaffray | Underweight |
| May-10-16 | Reiterated | RBC Capital Mkts | Underperform |
| Jan-06-16 | Reiterated | Piper Jaffray | Underweight |
| Jan-06-16 | Reiterated | RBC Capital Mkts | Underperform |
| Nov-04-15 | Downgrade | RBC Capital Mkts | Outperform → Underperform |
| Sep-09-15 | Downgrade | Piper Jaffray | Neutral → Underweight |
| Aug-03-15 | Reiterated | RBC Capital Mkts | Outperform |
| May-11-15 | Downgrade | JP Morgan | Neutral → Underweight |
| May-11-15 | Reiterated | MLV & Co | Hold |
| Apr-16-15 | Reiterated | RBC Capital Mkts | Outperform |
View All
Mannkind Corp Stock (MNKD) Latest News
FDA accepts application for MannKind inhaled insulin in kids - MassDevice
How MannKind Corporation stock responds to policy changesJuly 2025 Spike Watch & Safe Entry Point Identification - newser.com
MannKind (MNKD) Seeks FDA Approval for Afrezza in Younger Patien - GuruFocus
Is MannKind Corporation stock poised for growth2025 Technical Overview & Stepwise Swing Trade Plans - newser.com
MannKind (MNKD) Advances Inhaled Insulin for Pediatric Diabetes - GuruFocus
FDA accepts MannKind’s application for inhaled insulin in children - Investing.com
MannKind Corporation Submits Supplemental Biologics License Application for Needle-Free Afrezza Inhalation Powder for Pediatric Diabetes Treatment - Quiver Quantitative
Real time scanner hits for MannKind Corporation explainedMarket Trend Review & Free Reliable Trade Execution Plans - newser.com
MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes - Yahoo Finance
HC Wainwright & Co. Reiterates Buy Rating for MNKD with $11 PT | MNKD Stock News - GuruFocus
MannKind Corp. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
MannKind (NASDAQ:MNKD) Given "Hold (C)" Rating at Weiss Ratings - MarketBeat
Using data models to predict MannKind Corporation stock movement2025 Market Sentiment & Consistent Income Trade Ideas - newser.com
MannKind completes acquisition of scPharmaceuticals in $296.5 million deal - Investing.com
Risk adjusted return profile for MannKind Corporation analyzedWeekly Trade Analysis & Accurate Technical Buy Alerts - newser.com
Heatmap analysis for MannKind Corporation and competitorsJuly 2025 Spike Watch & Verified Swing Trading Watchlist - newser.com
How moving averages guide MannKind Corporation tradingWatch List & Weekly Momentum Picks - newser.com
MannKind (NASDAQ:MNKD) Upgraded at Zacks Research - MarketBeat
MannKind completes acquisition of scPharmaceuticals By Investing.com - Investing.com Canada
MannKind completes acquisition of scPharmaceuticals; SCPH to be delisted from Nasdaq - Investing.com
MannKind (MNKD) Completes Acquisition of scPharmaceuticals to Bo - GuruFocus
MannKind completes acquisition of scPharmaceuticals - Investing.com
MannKind Corporation Completes Acquisition of scPharmaceuticals Inc. to Enhance Revenue Growth and Expand Cardiometabolic Therapy Portfolio - Quiver Quantitative
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care - Yahoo Finance
>$370M annualized run rate: MannKind completes scPharmaceuticals acquisition, adds FUROSCIX - Stock Titan
A Fresh Look at MannKind (MNKD) Valuation Following Leadership Change with New Chief Medical Officer - simplywall.st
Does MannKind (NASDAQ:MNKD) Deserve A Spot On Your Watchlist? - Yahoo Finance
Why MannKind Corporation (NNFN) stock is trending on social mediaEarnings Summary Report & Safe Capital Growth Stock Tips - newser.com
How Dr. Ajay Ahuja’s Appointment at MannKind (MNKD) Has Changed Its Investment Story - simplywall.st
Assessing MannKind’s Share Price After FDA Clears Pediatric Use for Afrezza in 2025 - simplywall.st
Key metrics from MannKind Corporation’s quarterly dataRate Cut & Community Trade Idea Sharing - newser.com
Published on: 2025-10-02 20:45:52 - newser.com
Revolution Medicines hires Mirati, ALX vet Sandler - biocentury.com
MannKind Gets A Price Bump As Pipeline Progresses - Finimize
Is MannKind Corporation (NNFN) stock undervalued historicallyMarket Activity Summary & Daily Entry Point Trade Alerts - newser.com
Is MannKind Corporation a good long term investmentSector ETF Performance & Take Advantage of Momentum Stocks - earlytimes.in
MannKind (MNKD) Appoints New Chief Medical Officer - GuruFocus
MNKD Appoints New Chief Medical Officer to Strengthen Leadership Team - GuruFocus
MannKind appoints Ajay Ahuja as chief medical officer - Investing.com
MannKind Corporation Appoints Dr. Ajay Ahuja as Chief Medical Officer - Quiver Quantitative
Former Global Medical Head at Allergan: Dr. Ajay Ahuja Joins MannKind as Chief Medical Officer - Stock Titan
Will MannKind Corporation (NNFN) stock see insider accumulationJuly 2025 Rallies & Stock Timing and Entry Methods - newser.com
Will a bounce in MannKind Corporation offer an exitEarnings Overview Summary & Community Verified Swing Trade Signals - newser.com
Non Tuberculous Mycobacterial Infections Market Dynamics - openPR.com
MannKind (NASDAQ:MNKD) Shares Down 5%Time to Sell? - MarketBeat
MannKind (NASDAQ:MNKD) Earns Buy Rating from HC Wainwright - MarketBeat
Should you hold or exit MannKind Corporation nowWeekly Stock Recap & Scalable Portfolio Growth Ideas - newser.com
Price action breakdown for MannKind CorporationQuarterly Profit Report & Free Technical Confirmation Trade Alerts - newser.com
MannKind Corporation (NASDAQ:MNKD) Sees Significant Drop in Short Interest - MarketBeat
Insider Selling: MannKind (NASDAQ:MNKD) Insider Sells 47,000 Shares of Stock - MarketBeat
Mannkind Corp Stock (MNKD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):